

GENERAL ANNOUNCEMENT::HYPHENS PHARMA RECEIVES UK PATENT FOR CERADAN ADVANCED

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

13-Jul-2020 17:38:51

Status

New

Announcement Sub Title

HYPHENS PHARMA RECEIVES UK PATENT FOR CERADAN ADVANCED

Announcement Reference

SG200713OTHRKE9I

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

Attachments

[Hyphens Press%20Release Ceredan A%20Patent 130720.pdf](#)

Total size =245K MB

Media Release

Hyphens Pharma receives UK patent for Ceradan® Advanced

- **Patents for Ceradan® Advanced are pending in another 13 countries/ region**

Singapore, 13 July 2020 – Hyphens Pharma International Limited (“凯帆药剂国际有限公司”, “Hyphens Pharma”, or the “Company”, and together with its subsidiaries, the “Group”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its patent for Ceradan® Advanced has been granted in the United Kingdom (UK) and is pending approval in 13 countries/ region such as Singapore, Malaysia, Vietnam, China, Europe, USA, etc.

Ceradan® Advanced is a patented next-generation emollient therapy that is scientifically formulated for eczema-prone skin conditions. Ceradan® Advanced sustainably lowers the skin pH for up to 12 hours to induce skin lipids production and suppresses skin cell breakdown. This helps to accelerate optimal skin barrier repair and restoration.

Mr Lim See Wah, Chief Executive Officer of Hyphens Pharma commented: “The patent approval of Ceradan® Advanced is an affirmation of our research-based approach to product development. Patenting our Intellectual Property is strategic as it contributes towards the expansion of Ceradan® Advanced’s branding. Even in turbulent times such as the COVID-19 pandemic, Hyphens will continually seek to improve on our products. We are also happy to launch two new products - Ceradan® Gentle Cleanser and Ceradan® Hand Lotion Sanitiser, so as to help users care for their skin while addressing the increased need for better sanitation and hygiene.”

Ceradan® Hand Lotion Sanitiser is a high-performance hand lotion sanitiser that protects hands against harmful germs and moisturises with ceramide-dominant essential skin lipids to maintain

a healthy skin protective barrier. Formulated with a pH of 5.5, it is hypoallergenic and free from colourants and fragrances.

Ceradan® Gentle Cleanser is a gentle, soap-free, face and body cleanser that not only hydrates and soothes, but also rebuilds the skin barrier as it cleans. It is hypoallergenic, free from sodium lauryl sulphate/sodium laureth sulfate (SLS/SLES), paraben, colourants, and fragrances.

Both the Ceradan® Gentle Cleanser and Ceradan® Hand Lotion Sanitiser are suitable for all skin types, including eczema-prone, dry and sensitive skin, and are currently available in retail pharmacies such as Guardian and Watsons.

The aforementioned products are expected to contribute positively to the revenue and profitability of the Group, but there will not be a material effect on the net tangible assets or earnings per share of the Group for the financial year ending 31 December 2020.



End.

About Hyphens Pharma International Limited

(www.hyphensgroup.com)

Hyphens Pharma International Limited and its subsidiaries (the "**Group**") is Singapore's leading specialty pharmaceutical and consumer healthcare group leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering six additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia, Oman and Bangladesh.

Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

Issued on behalf of the Company by Cogent Communications Pte Ltd.

For enquiries, please contact:

Ms Candy Soh, Tel: (65) 6704-9284, Mob: (65) 9816-8391

Email: candysoh@kogentcomms.com

Mr Gerald Woon, Tel: (65) 6704-9268, Mob: (65) 9694-8364

Email: woon@kogentcomms.com

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.